BAVARIAN NORDIC/S (BVNRY) Issues Earnings Results

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) released its earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.04), reports. BAVARIAN NORDIC/S had a negative net margin of 126.80% and a negative return on equity of 19.43%. The company had revenue of $19.29 million for the quarter, compared to the consensus estimate of $21.15 million.

BAVARIAN NORDIC/S stock opened at $7.62 on Friday. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $10.78. The company has a quick ratio of 5.84, a current ratio of 6.15 and a debt-to-equity ratio of 0.17.

Separately, Zacks Investment Research downgraded shares of BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th.

TRADEMARK VIOLATION WARNING: “BAVARIAN NORDIC/S (BVNRY) Issues Earnings Results” was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Story: What strategies should day traders use to execute a trade?


Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.